Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 14,950 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Digestive System Clear all
Recruiting Phase 1Phase 2 Interventional

Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors

NCT06750185
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
BNT317 DL1, BNT317 DL2, BNT317 DL3, BNT317 DL4, BNT317 DL5, BNT317 DL6, BNT317 selected DLA, BNT317 selected DLB, SoC chemotherapy 1, SoC chemotherapy 2
Biological · Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
7
States / cities
Louisville, Kentucky • Grand Rapids, Michigan • Huntersville, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 21, 2026, 10:23 PM EDT
Completed Phase 2 Interventional

Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment.

NCT06247735
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
K-808 (Dose A), K-808 (Dose B), Placebo
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
21
States / cities
Tucson, Arizona • Coronado, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 21, 2026, 10:23 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Clinical Study to Assess the Efficacy of Once-daily IMM-124E (Travelan®) in a Controlled Human Infection Model.

NCT05933525
View directory record Official record
Conditions
Diarrhea, Travelers Diarrhea, Infectious Diarrhea
Interventions
Travelan, Placebo
Biological · Other
Lead sponsor
Immuron Ltd.
Industry
Eligibility
18 Years to 50 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 21, 2026, 10:23 PM EDT
Completed Phase 4 Interventional Results available

Amitiza in Constipation Associated With PD (Parkinson's Disease)

NCT00908076
View directory record Official record
Conditions
Parkinson's Disease
Interventions
LUBIPROSTONE
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 85 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Tampa, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 29, 2022 · Synced Oct 21, 2026, 10:23 PM EDT
Completed Phase 2 Interventional Results available

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer

NCT01395017
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
dasatinib, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2016 · Synced Oct 21, 2026, 10:23 PM EDT
Completed Phase 1Phase 2 Interventional

Carbon Monoxide-Saturated Medium for Islet Isolation

NCT02567240
View directory record Official record
Conditions
Chronic Pancreatitis
Interventions
Carbon monoxide-bubbled mediums
Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 69 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 4, 2019 · Synced Oct 21, 2026, 10:23 PM EDT
Completed Phase 2 Interventional

HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-Diabetes

NCT05623189
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH), Type 2 Diabetes
Interventions
HTD1801, Placebo
Drug
Lead sponsor
HighTide Therapeutics (Hong Kong) Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
43
States / cities
Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 21, 2026, 10:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Raw Versus Other Milk Sources on Lactose Digestion

NCT01129791
View directory record Official record
Conditions
Lactose Intolerance
Interventions
Raw Milk, Pasteurized Milk, Non-dairy milk
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Oct 21, 2026, 10:23 PM EDT
Terminated No phase listed Observational

Study Evaluating Metabolic Syndrome in Subjects Undergoing Gastric Bypass Bariatric Syndrome

NCT00283374
View directory record Official record
Conditions
Morbid Obesity, Metabolic Disease
Interventions
Laparoscopic Roux-en-Y Gastric Bypass
Procedure
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
10
States / cities
Irvine, California • Orange, California • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated May 18, 2006 · Synced Oct 21, 2026, 10:23 PM EDT
Recruiting Not applicable Interventional

Effect of Blenderized Enteral Tube Feeds on Pediatric Upper Gastrointestinal Tract Physiology

NCT04900597
View directory record Official record
Conditions
Enteral Feeding Intolerance
Interventions
Elecare Jr, Nourish, Real Foods Blends
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
1 Year and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 21, 2026, 10:23 PM EDT
Completed No phase listed Observational

Bartonella in Liver Transplant Patients

NCT02595710
View directory record Official record
Conditions
Cryptogenic Cirrhosis, Cryptogenic Chronic Hepatitis
Interventions
skin punch biopsy collection, Blood collection, Urine sample collection
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 21, 2026, 10:23 PM EDT
Recruiting Phase 2 Interventional

Efficacy and Safety of Oral Rifaximin in Patients With Active Microscopic Colitis

NCT04043897
View directory record Official record
Conditions
Microscopic Colitis
Interventions
Rifaximin 550mg
Drug
Lead sponsor
Eugene F Yen, MD
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 15, 2021 · Synced Oct 21, 2026, 10:23 PM EDT
Completed Phase 1 Interventional

A Dose-Escalation Study of MDX-1100 in Patients With Active Ulcerative Colitis

NCT00295282
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
MDX-1100 (anti-CXCL10 human monoclonal antibody)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
5
States / cities
Los Angeles, California • Largo, Florida • Chevy Chase, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2010 · Synced Oct 21, 2026, 10:23 PM EDT
Terminated Phase 2 Interventional Results available

A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001)

NCT04583423
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
MK-3655, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
48
States / cities
Tucson, Arizona • North Little Rock, Arkansas • Canoga Park, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 21, 2026, 10:23 PM EDT
Completed No phase listed Observational

Project BEST: Buprenorphine Entry Into Substance Abuse Treatment

NCT02583243
View directory record Official record
Conditions
Opioid-related Disorders, HIV Infections, Hepatitis C, Chronic, Depression
Interventions
MET/CBT based individualized counseling, Buprenorphine
Behavioral · Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 21, 2026, 10:23 PM EDT
Completed Phase 2 Interventional

GW572016, An Oral Drug For Colorectal Cancer Patients Having Prior Therapy With 5-FU Plus CPT-11 And/Or Oxaliplatin

NCT00044343
View directory record Official record
Conditions
Colorectal Cancer
Interventions
lapatinib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
50
States / cities
Los Angeles, California • Poway, California • Torrington, Connecticut + 46 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2014 · Synced Oct 21, 2026, 10:23 PM EDT
Completed Phase 2 Interventional Results available

Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer (mCRC)

NCT01374425
View directory record Official record
Conditions
Colorectal Cancer
Interventions
5-Fluorouracil, Bevacizumab, Irinotecan, Leucovorin, Oxaliplatin, Capecitabine
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
65
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Bellflower, California + 59 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2016 · Synced Oct 21, 2026, 10:23 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Immune Responses to Gluten

NCT05209568
View directory record Official record
Conditions
Celiac Disease, Malabsorption Syndromes, Digestive System Disease, Intestinal Disease, Gastrointestinal Diseases, Gluten Sensitivity, Celiac Disease in Children
Interventions
Gluten Powder
Dietary Supplement
Lead sponsor
Boston Children's Hospital
Other
Eligibility
2 Years to 101 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
2
States / cities
Aurora, Colorado • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 21, 2026, 10:23 PM EDT
Completed Phase 3 Interventional

A Double-Blind, Placebo-Controlled Trial of Albendazole in HIV-Positive Patients With Intestinal Microsporidiosis

NCT00002191
View directory record Official record
Conditions
Protozoan Infections, HIV Infections
Interventions
Albendazole
Drug
Lead sponsor
SmithKline Beecham
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
San Francisco, California • Washington D.C., District of Columbia • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 21, 2026, 10:23 PM EDT
Terminated Phase 2 Interventional Results available

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

NCT04383210
View directory record Official record
Conditions
Locally Advanced Solid Tumor, Metastatic Solid Tumor, Pancreatic Cancer, Lung Cancer, Head and Neck Cancer, Breast Cancer, Kidney Cancer, Colorectal Cancer, Bladder Cancer, Ovarian Cancer, Sarcoma, Gallbladder Cancer, Bile Duct Cancer, Esophageal Cancer, Uterine Cancer, Cholangiocarcinoma, Prostate Cancer
Interventions
Seribantumab
Drug
Lead sponsor
Elevation Oncology
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
35
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fountain Valley, California + 32 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Oct 21, 2026, 10:23 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis

NCT03911713
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-561, IVA, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
30
States / cities
Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Oct 21, 2026, 10:23 PM EDT
Completed No phase listed Observational

Identifying the Role of Symptom Outcomes and Biomarkers in Survival in Patients With Metastatic Pancreatic Cancer

NCT00805688
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Questionnaires, Blood Draws, Pedometer
Behavioral · Procedure · Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 6, 2018 · Synced Oct 21, 2026, 10:23 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

To Compare Artificial Intelligence Software Aided Adenoma Detection in Screening Colonoscopies Versus Standard Colonoscopy Without Artificial Intelligence Software Assistance in Participants Between 45 and 75 Years of Age

NCT04196088
View directory record Official record
Conditions
Colorectal Adenoma, Colorectal Polyp, Colorectal Adenocarcinoma, Colorectal SSA
Interventions
Ultivision Artificial Intelligence Software, No Artificial Intelligence Software enhancement
Device
Lead sponsor
Docbot, Inc.
Industry
Eligibility
45 Years to 75 Years
Enrollment
978 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
9
States / cities
Birmingham, Alabama • San Diego, California • Kansas City, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2021 · Synced Oct 21, 2026, 10:23 PM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy

NCT03695185
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
Ravagalimab 600 mg, Ravagalimab 300 mg
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
12
States / cities
Tucson, Arizona • Huntington Beach, California • Lakewood, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Oct 21, 2026, 10:23 PM EDT